Trials / Completed
CompletedNCT00523432
A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- University of Chicago · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the trial is to determine the recommended phase II dose of weekly intravenous topotecan in combination with a fixed dose (25 mg or 15 mg) of weekly intravenous temsirolimus in patients with and without prior pelvic radiation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Topotecan | Weekly doses via IV infusion. Dose will be assigned based on time of study entry. |
| DRUG | CCI-779 (temsirolimus) | Weekly 25mg dose via IV infusion. |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2009-09-01
- Completion
- 2010-12-01
- First posted
- 2007-08-31
- Last updated
- 2013-09-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00523432. Inclusion in this directory is not an endorsement.